Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Bonavida

Showing results (151-160 of 192) with videos related to

Pageof 20
Sort By:
Nitric Oxide : Biology and Chemistry|September 10, 2008
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1Sara Huerta-Yepez, Mario Vega, Saul E Escoto-Chavez, et al.
Biochemical and Biophysical Research Communications|September 7, 2005
Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosationFumiya Hongo, Hermes Garban, Sara Huerta-Yepez, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 25, 2003
Regulated interleukin-10 expression prevents chronic rejection of transplanted heartsMichael P Fischbein, James Yun, Hillel Laks, et al.
Leukemia & Lymphoma|October 25, 2008
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugsMario I Vega, Melissa Martinez-Paniagua, Ali R Jazirehi, et al.
Cancer|September 24, 2004
Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinomaYoichi Mizutani, Hiroki Matsubara, Kosuke Yamamoto, et al.
Molecular Cancer Therapeutics|January 24, 2012
Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugsMelisa A Martinez-Paniagua, Mario I Vega, Sara Huerta-Yepez, et al.
Leukemia Research|July 24, 2010
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivoEric Sanchez, Jing Shen, Jeffrey Steinberg, et al.
International Journal of Oncology|June 15, 2013
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabineKandasamy Hariharan, Peter Chu, Tracey Murphy, et al.
Nitric Oxide : Biology and Chemistry|December 19, 2012
Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancerSara Huerta-Yepez, Stavroula Baritaki, Guillermina Baay-Guzman, et al.
International Journal of Oncology|September 24, 2015
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapyGabriel G Vega, Luz Areli Franco-Cea, Sara Huerta-Yepez, et al.
Pageof 20

Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Nitric Oxide : Biology and Chemistry|September 10, 2008
Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1Sara Huerta-Yepez, Mario Vega, Saul E Escoto-Chavez, et al.
Biochemical and Biophysical Research Communications|September 7, 2005
Inhibition of the transcription factor Yin Yang 1 activity by S-nitrosationFumiya Hongo, Hermes Garban, Sara Huerta-Yepez, et al.
The Journal of Thoracic and Cardiovascular Surgery|July 25, 2003
Regulated interleukin-10 expression prevents chronic rejection of transplanted heartsMichael P Fischbein, James Yun, Hillel Laks, et al.
Leukemia & Lymphoma|October 25, 2008
The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugsMario I Vega, Melissa Martinez-Paniagua, Ali R Jazirehi, et al.
Cancer|September 24, 2004
Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinomaYoichi Mizutani, Hiroki Matsubara, Kosuke Yamamoto, et al.
Molecular Cancer Therapeutics|January 24, 2012
Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugsMelisa A Martinez-Paniagua, Mario I Vega, Sara Huerta-Yepez, et al.
Leukemia Research|July 24, 2010
The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivoEric Sanchez, Jing Shen, Jeffrey Steinberg, et al.
International Journal of Oncology|June 15, 2013
Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabineKandasamy Hariharan, Peter Chu, Tracey Murphy, et al.
Nitric Oxide : Biology and Chemistry|December 19, 2012
Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancerSara Huerta-Yepez, Stavroula Baritaki, Guillermina Baay-Guzman, et al.
International Journal of Oncology|September 24, 2015
Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapyGabriel G Vega, Luz Areli Franco-Cea, Sara Huerta-Yepez, et al.
Pageof 20